Retinal Vessel Density and Retinal Nerve Fiber Layer Thickness: A Prospective Study of One-Year Follow-Up of Patients with Parkinson’s Disease

Objective This study aims to compare the superficial vascular density from the macular region and the retinal nerve fiber layer (RNFL) thickness from the optic disc region between Parkinson’s disease (PD) patients and controls. Methods We enrolled 56 idiopathic PD patients, totaling 86 eyes (PD group), and 45 sex- and age-matched healthy individuals, amounting to 90 eyes (control group). All subjects underwent examination using Zeiss wide-field vascular optical coherence tomography (OCT) (Cirrus HD-OCT 5000 Carl Zeiss, Germany), with a scanning range of 3 mm × 3 mm. We divided the images into two concentric circles with diameters of 1 mm and 3 mm at the macular fovea’s center. Patients with PD were evaluated during their “off” phase using the Unified Parkinson’s Disease Rating Scale III (UPDRS-III) and the Hoehn-Yahr scale (H-Y scale) to assess disease severity. Results The PD group exhibited significantly lower RNFL thickness (106.13±12.36 μm) compared to the control group (115.95±11.37 μm, P < 0.05). Similarly, the superficial retinal vessel length density was significantly lower in the PD group (20.7 [19.62, 22.17] mm−1) than in the control group (21.79±1.16 mm−1, P < 0.05). Correlation analysis revealed a negative correlation between RNFL thickness and UPDRS III score (rs=−0.036, P=0.037), and RNFL thickness tended to decrease with increasing severity of movement disorders. However, during the 6 and 12-month follow-up of some PD patients, we observed no progressive thinning of the RNFL or decreased superficial vascular density. Conclusion PD patients show retinal structural damage characterized by RNFL thinning and reduced retinal vessel length density. However, RNFL thickness did not correlate with vascular density nor did it decrease with the disease’s progression.

[1]  Xue Li,et al.  Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease , 2023, Journal of the Neurological Sciences.

[2]  M. Breteler,et al.  Visual impairment and retinal and brain neurodegeneration: A population‐based study , 2023, Human brain mapping.

[3]  Yu Deng,et al.  Evaluation of retina and microvascular changes in the patient with Parkinson’s disease: A systematic review and meta-analysis , 2022, Frontiers in Medicine.

[4]  A. Regev,et al.  Temporal single-cell atlas of non-neuronal retinal cells reveals dynamic, coordinated multicellular responses to central nervous system injury , 2022, bioRxiv.

[5]  M. Hallett,et al.  Eye Movement Disorders in Movement Disorders , 2022, Movement disorders clinical practice.

[6]  J. Qu,et al.  Retinal Dopamine D2 Receptors Participate in the Development of Myopia in Mice , 2022, Investigative ophthalmology & visual science.

[7]  B. Lacoste,et al.  From Neurodevelopmental to Neurodegenerative Disorders: The Vascular Continuum , 2021, Frontiers in Aging Neuroscience.

[8]  P. Chan,et al.  Prevalence of Parkinson's Disease: A Community‐Based Study in China , 2021, Movement disorders : official journal of the Movement Disorder Society.

[9]  Dan Zhang,et al.  Retinal Flow Density Changes in Early-stage Parkinson’s Disease Investigated by Swept-Source Optical Coherence Tomography Angiography , 2021, Current eye research.

[10]  R. Zhao,et al.  MSC-Derived Exosomes can Enhance the Angiogenesis of Human Brain MECs and Show Therapeutic Potential in a Mouse Model of Parkinson's Disease , 2021, Aging and disease.

[11]  Wan-Hazabbah Wan Hitam,et al.  Retinal Nerve Fiber Layer and Macular Thickness in Parkinson's Disease Patients , 2021, Cureus.

[12]  M. Zappia,et al.  Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease. , 2021, Parkinsonism & Related Disorders.

[13]  M. Tsolaki,et al.  Ocular biomarkers and their role in the early diagnosis of neurocognitive disorders , 2021, European journal of ophthalmology.

[14]  X. Mu,et al.  Genetic control of retinal ganglion cell genesis , 2021, Cellular and Molecular Life Sciences.

[15]  M. Droździk,et al.  Arterial Blood Pressure Variability and Other Vascular Factors Contribution to the Cognitive Decline in Parkinson’s Disease , 2021, Molecules.

[16]  Joan W. Miller,et al.  Retinal applications of swept source optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) , 2021, Progress in Retinal and Eye Research.

[17]  Jia-Yi Li,et al.  Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation , 2021, Scientific Reports.

[18]  Cason B. Robbins,et al.  Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease. , 2020, JAMA ophthalmology.

[19]  Yujie Wang,et al.  Central retina changes in Parkinson’s disease: a systematic review and meta-analysis , 2020, Journal of Neurology.

[20]  P. Yu-Wai-Man,et al.  Optical Coherence Tomography Angiography Reveals Distinct Retinal Structural and Microvascular Abnormalities in Cerebrovascular Disease , 2020, Frontiers in Neuroscience.

[21]  Lu Shen,et al.  Combination of optical coherence tomography (OCT) and OCT angiography increases diagnostic efficacy of Parkinson's disease. , 2020, Quantitative imaging in medicine and surgery.

[22]  R. Monastero,et al.  Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study , 2020, Journal of Neurology.

[23]  B. Franco,et al.  α-synuclein overexpression in the retina leads to vision impairment and degeneration of dopaminergic amacrine cells , 2020, Scientific Reports.

[24]  A. Xie,et al.  Association Between Stroke and Parkinson’s Disease: a Meta-analysis , 2020, Journal of Molecular Neuroscience.

[25]  Mahmut Atum,et al.  Retinal morphological changes during the two years of follow-up in Parkinson's disease. , 2020, Ideggyogyaszati szemle.

[26]  Benjamin R. Kummer,et al.  Associations between cerebrovascular risk factors and parkinson disease , 2019, Annals of neurology.

[27]  W. Kwapong,et al.  CHARACTERIZATION BY FRACTAL DIMENSION ANALYSIS OF THE RETINAL CAPILLARY NETWORK IN PARKINSON DISEASE. , 2019, Retina.

[28]  Benedict Michael,et al.  Faculty Opinions recommendation of Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[29]  Z. Çolakoglu,et al.  Functional and morphological assessment of ocular structures and follow-up of patients with early-stage Parkinson’s disease , 2019, International Ophthalmology.

[30]  V. Baekelandt,et al.  Retinal α-synuclein deposits in Parkinson’s disease patients and animal models , 2019, Acta Neuropathologica.

[31]  M. Cordeiro,et al.  Oculo‐visual abnormalities in Parkinson's disease: Possible value as biomarkers , 2018, Movement disorders : official journal of the Movement Disorder Society.

[32]  Jianhua Wang,et al.  Retinal Microvascular Impairment in the Early Stages of Parkinson's Disease. , 2018, Investigative ophthalmology & visual science.

[33]  M. Carbonelli,et al.  Patterns of Retinal Ganglion Cell Damage in Neurodegenerative Disorders: Parvocellular vs Magnocellular Degeneration in Optical Coherence Tomography Studies , 2017, Front. Neurol..

[34]  James G. Fujimoto,et al.  The Definition, Rationale, and Effects of Thresholding in OCT Angiography. , 2017, Ophthalmology. Retina.

[35]  M. Jin,et al.  MDS clinical diagnostic criteria for Parkinson’s disease in China , 2017, Journal of Neurology.

[36]  Jose A Crespo,et al.  Evaluation of Progressive Visual Dysfunction and Retinal Degeneration in Patients With Parkinson's Disease. , 2017, Investigative ophthalmology & visual science.

[37]  G. Malaguarnera,et al.  The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain , 2016, Acta neuropathologica communications.

[38]  I. Selesnick,et al.  The avascular zone and neuronal remodeling of the fovea in Parkinson disease , 2015, Annals of clinical and translational neurology.

[39]  Ivan Bodis-Wollner,et al.  α‐synuclein in the inner retina in parkinson disease , 2014, Annals of neurology.

[40]  F. Ascaso,et al.  Development of a prediction formula of Parkinson disease severity by optical coherence tomography , 2014, Movement disorders : official journal of the Movement Disorder Society.

[41]  Aysu Şen,et al.  Effects of Levodopa on Retina in Parkinson Disease , 2014, European journal of ophthalmology.

[42]  L. Pablo,et al.  Retinal thinning and correlation with functional disability in patients with Parkinson's disease , 2013, British Journal of Ophthalmology.

[43]  Axel Petzold,et al.  The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment , 2012, PloS one.

[44]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[45]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[46]  A. Albanese Diagnostic criteria for Parkinson's disease , 2003, Neurological Sciences.

[47]  T. Chan-Ling,et al.  Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. , 2000, Investigative ophthalmology & visual science.

[48]  C. Mao,et al.  Progressive Changes in the Retinal Structure of Patients with Parkinson's Disease. , 2018, Journal of Parkinson's disease.

[49]  M. Schwartz,et al.  The retina as a window to the brain—from eye research to CNS disorders , 2013, Nature Reviews Neurology.